Shopping Cart
- Remove All
Your shopping cart is currently empty
Tazemetostat hydrobromide
Catalog No. T17002Cas No. 1467052-75-0
Alias EPZ-6438 hydrobromide, E-7438 hydrobromide
Tazemetostat hydrobromide (E-7438 hydrobromide) is a potent and selective EZH2 inhibitor. Tazemetostat hydrobromide inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 (Ki: 2.5 nM). Tazemetostat hydrobromide also inhibits EZH1 (IC50: 392 nM).
Tazemetostat hydrobromide
Catalog No. T17002Alias EPZ-6438 hydrobromide, E-7438 hydrobromideCas No. 1467052-75-0
Tazemetostat hydrobromide (E-7438 hydrobromide) is a potent and selective EZH2 inhibitor. Tazemetostat hydrobromide inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 (Ki: 2.5 nM). Tazemetostat hydrobromide also inhibits EZH1 (IC50: 392 nM).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $36 | In Stock | |
| 5 mg | $55 | In Stock | |
| 10 mg | $74 | In Stock | |
| 50 mg | $97 | In Stock | |
| 100 mg | $162 | In Stock | |
| 200 mg | $243 | In Stock | |
| 500 mg | $397 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $76 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Tazemetostat hydrobromide"
EPZ015666
GSK3235025
T60761616391-65-1
EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 enzymatic activity.
- $42
Size
QTY
MRTX-1719
T402542630904-45-7
MRTX-1719 is a potent and selective inhibitor of the PRMT5/MTA complex with an IC50 value of <10 nM against PRMT5/MTAMTAPDELSDMA cell lines.
- $398
Size
QTY
Tazemetostat
Cited
EPZ6438, E-7438
T17881403254-99-8
Tazemetostat (EPZ6438) is a histone methyltransferase EZH2 inhibitor (IC50=11 nM) that is orally active, selective, and SAM-competitive. Tazemetostat exhibits antitumor activity and may be used for the treatment of epithelioid sarcoma/follicular lymphoma.
- $59
Size
QTY
CitedPiribedil
Trivastan, Trivastal, EU-4200, ET-495
T32783605-01-4
Piribedil (Trivastan) is a dopamine D2 agonist, used in the treatment of Parkinson's disease.
- $52
Size
QTY
GSK126 Cited
GSK2816126A, EZH2 inhibitor
T20791346574-57-9
GSK126 (GSK2816126A) is a excellently specific EZH2 methyltransferase inhibitor ( IC50=9.9 nM).
- $37
Size
QTY
CitedXY1
T71571624117-53-8
XY1 is a close analogue of SGC707 (a potent, selective, and non-competitive inhibitor of PRMT3 with IC50 of 31 nM), intended as a negative control for SGC707 in studies involving PRMT3 action.
- $31
Size
QTY
AMI-1 free acid
T22239134-47-4
AMI-1 free acid is a potent, cell-permeable, and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with inhibitory concentration 50 (IC50) values of 8.8 μM for human PRMT1 and 3.0 μM for yeast-Hmt1p. It achieves its PRMTs inhibitory activity by obstructing peptide-substrate binding [1].
- $40
Size
QTY
MS37452
T21767423748-02-1
MS37452 is a competitive inhibitor of CBX7 chromodomain binding to H3K27me3 (Ki = 43 µM).
- $29
Size
QTY
BIX-01294 trihydrochloride Cited
BIX 01294
T19591392399-03-9
BIX-01294 trihydrochloride is an inhibitor of G9a histone methyltransferase.In a cell-free assay, the IC50=2.7 μM for G9a histone methyltransferase.
- $30
Size
QTY
CitedUNC 0631
UNC0631
T23541320288-19-4
UNC 0631 is a effectvie histone methyltransferase G9a inhibitor (IC50=4 nM).
- $42
Size
QTY
Select Batch
Purity:99.03%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Tazemetostat hydrobromide (E-7438 hydrobromide) is a potent and selective EZH2 inhibitor. Tazemetostat hydrobromide inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 (Ki: 2.5 nM). Tazemetostat hydrobromide also inhibits EZH1 (IC50: 392 nM). |
| Targets&IC50 | EZH2 (WT):2.5 nM (Ki), EZH2:11 nM (in peptide assay), EZH2:16 nM (in nucleosome assay), EZH2 (rat):4 nM, EZH1:392 nM |
| In vitro | Tazemetostat hydrobromide inhibits Rat EZH2 (IC50: 4 nM). Tazemetostat hydrobromide inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat hydrobromide inhibits multi wild-type and mutant lymphoma cell lines proliferation with IC50s of 0.49 nM-7.6 μM [1]. |
| In vivo | Tazemetostat (250 or 500 mg/kg twice daily for 21-28 days) practically eliminates the fast-growing G401 tumors [1]. |
| Alias | EPZ-6438 hydrobromide, E-7438 hydrobromide |
| Molecular Weight | 653.65 |
| Formula | C34H45BrN4O4 |
| Cas No. | 1467052-75-0 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (152.99 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Tazemetostat hydrobromide | purchase Tazemetostat hydrobromide | Tazemetostat hydrobromide cost | order Tazemetostat hydrobromide | Tazemetostat hydrobromide chemical structure | Tazemetostat hydrobromide in vivo | Tazemetostat hydrobromide in vitro | Tazemetostat hydrobromide formula | Tazemetostat hydrobromide molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.